Latest Equity Capital Raising News

KMD Brands has successfully completed a $44.2 million institutional equity raise as part of a larger $58.5 million entitlement offer, setting the stage for its retail offer opening next week.

Great Southern Mining has initiated deep diamond drilling at its Golden Boulder discovery in Western Australia, supported by government co-funding and a recent capital raise. This marks a pivotal step in exploring the source of multiple gold mineralisation trends within the Duketon Gold Project.

Reach Resources Limited has announced a pro-rata entitlement issue aiming to raise up to $3.15 million to fund exploration and working capital, with key directors and the CEO committing to participate.

WA Kaolin Limited has announced a $34.9 million recapitalisation plan involving a non-renounceable entitlement issue and debt conversion to strengthen its balance sheet and fund operational improvements at its Wickepin kaolin project.

TerraCom Limited reported a significant half-year loss amid falling coal prices and production challenges, completing a $56 million capital raise to strengthen its financial position.

Horizon Minerals has launched a Share Purchase Plan allowing eligible shareholders in Australia and New Zealand to buy additional shares between $2,000 and $30,000. The offer runs until 10 March 2026, with potential early closure depending on demand.

Contact Energy has announced a $525 million equity raise to accelerate its renewable energy projects, following a strong first half of FY26 with significant profit growth and strategic acquisitions.

Brightstar Resources has launched a $5 million Share Purchase Plan offering eligible shareholders discounted shares to fund key mining projects. The offer opens on 10 February and closes on 27 February 2026.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Alpha HPA Limited reports strong progress on its HPA First Project Stage 2 construction and secures binding supply contracts for 2026 in the booming semiconductor sector, while launching a $225 million equity raise to fund expansion.